Tissue-Engineered “Metastases”: Treatment of Hepatic Colon Tumors with a Dual Action Autotaxin Inhibitor-Lysophosphatidic Acid Receptor Antagonist
Open Access
- 20 August 2021
- journal article
- research article
- Published by Neoplasia Research in Journal of Cancer Research Updates
- Vol. 1 (1) , 69-77
Abstract
Lysophosphatidic acid (LPA) acts via G protein coupled receptors (GPCRs) to regulate critical cellular functions and pathophysiological levels of LPA or its receptors are linked to cancer initiation, progression and metastasis. LPA is biosynthesized by the lysophospholipase D activity of autotaxin(ATX/lysoPLD), a known factor for tumorigenesis. By attenuating both LPA signaling and LPA production, we expected to observe synergistic anti-cancer therapeutic effects. In vitro, treatment of human colon cancer cells (HCT 116) with BrP-LPA, a potent dual action ATX inhibitor and pan-LPA GPCR antagonist, significantly reduced cell proliferation, migration and invasion. Next, a tissue-engineered xenograft model to mimic hepatic metastasis of colon cancer was used to evaluate BrP-LPA efficacy in vivo. HCT 116 cells were suspended in Extracel™, a synthetic extracellular matrix (sECM), and injected directly into the livers of nude mice (n = 8). After 1 week, BrP-LPA in saline buffer was administered for two weeks by intraperitoneal injection (10 mg/kg) twice per week. Controls were injected with saline buffer only. The BrP-LPA treated group showed reduced liver tumor weight (p < 0.05) and reduced tumor volume (p < 0.05) relative to controls. This study is the first demonstration of the effects of a dual action ATX inhibitor/LPA antagonist on colon cancer cells, and the first example of a tissue-engineered hepatic colon cancer “metastases” as a platform for anti-cancer drug evaluation. The results suggest that attenuation of signaling through the LPA pathway offers a promising therapeutic target for reducing colon cancer growth and metastasis.Keywords
This publication has 40 references indexed in Scilit:
- Structural basis of substrate discrimination and integrin binding by autotaxinNature Structural & Molecular Biology, 2011
- Boronic acid-based inhibitor of autotaxin reveals rapid turnover of LPA in the circulationProceedings of the National Academy of Sciences, 2010
- Lysophosphatidic acid production and action: critical new players in breast cancer initiation and progressionBritish Journal of Cancer, 2010
- Inhibition of tumor growth and angiogenesis by a lysophosphatidic acid antagonist in an engineered three‐dimensional lung cancer xenograft modelCancer, 2010
- Evaluating dual activity LPA receptor pan-antagonist/autotaxin inhibitors as anti-cancer agents in vivo using engineered human tumorsProstaglandins & Other Lipid Mediators, 2009
- Dual Activity Lysophosphatidic Acid Receptor Pan-Antagonist/Autotaxin Inhibitor Reduces Breast Cancer Cell MigrationIn vitroand Causes Tumor RegressionIn vivoCancer Research, 2009
- Lysophosphatidic acid (LPA) and angiogenesisAngiogenesis, 2008
- α‐Substituted Phosphonate Analogues of Lysophosphatidic Acid (LPA) Selectively Inhibit Production and Action of LPAChemMedChem, 2007
- Orthotopic models of cancer for preclinical drug evaluationEuropean Journal of Cancer, 2004
- The emerging role of lysophosphatidic acid in cancerNature Reviews Cancer, 2003